Am J Cardiovasc Drugs. 2011;11(2):137-43. doi: 10.2165/11533650-000000000-00000.
Anthera Pharmaceuticals is developing an oral formulation of varespladib (A 001; A 002; A-001; A-002; LY 315920; LY 333013; LY315920; LY333013; S 3013; S 5920; S-3013; S-5920; Varespladib methyl) for once-daily treatment of acute coronary syndromes. Varespladib acts by inhibiting secretory phospholipase A2 (sPLA2) and the drug is currently being evaluated in approximately 6500 patients with acute coronary syndromes receiving atorvastatin in the placebo-controlled VISTA 16 (NCT01130246) trial being conducted in North America and Europe. This review discusses the development history and scientific profile of this new compound.
安特罗制药公司正在开发一种瓦瑞昔布（A001；A002；A-001；A-002；LY315920；LY333013；LY315920；LY333013；S3013；S5920；S-3013；S-5920；Varespladib methyl）的口服制剂，用于治疗急性冠状动脉综合征，每日一次。瓦瑞昔布通过抑制分泌型磷脂酶 A2（sPLA2）发挥作用，该药目前正在约 6500 名接受阿托伐他汀治疗的急性冠状动脉综合征患者中进行评估，该试验正在北美和欧洲进行，名为 VISTA16（NCT01130246），为安慰剂对照试验。这篇综述讨论了这种新型化合物的开发历史和科学概况。
